Register to receive a free Anesthesia, Respiratory, and Sleep Management Devices Market Report Suite for US synopsis and brochure
Inspire Medical Systems, Inc. (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (OSA), announced that Aetna Inc., one of the leading health plans in the United States, will provide coverage for the Company’s Inspire therapy, effective immediately. Aetna’s plan provides coverage for approximately 22 million members.
“We are very pleased to receive this positive coverage decision from Aetna. We believe this coverage decision is a major milestone and has the potential to facilitate patient and physician access to and interest in Inspire therapy,” said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. “There is a strong body of clinical data supporting Inspire therapy, including the 5-year STAR data, the ADHERE 300-patient registry data and other supportive publications. We believe our growing body of clinical and real-world data will be the basis for further coverage decisions by other major health plans.”
Under its policy, Aetna considers Inspire’s U.S. Food and Drug Administration (FDA) approved hypoglossal nerve neurostimulation device to be medically necessary for the treatment of moderate to severe OSA when a number of criteria are met. These include a previous attempt at continuous positive airway pressure (CPAP) treatment and patient selection consistent with FDA approval guidelines.
Inspire therapy is an innovative, closed-loop, minimally invasive solution that provides comfort and convenience, resulting in high compliance for patients with moderate to severe OSA. The safety and efficacy of Inspire therapy is supported by a significant body of clinical data, which includes a publication in the New England Journal of Medicine and more than 50 peer-reviewed publications. Inspire obtained CE Mark for its Inspire therapy in 2010 and FDA approval in 2014. To date, physicians have treated more than 3,000 patients worldwide with Inspire therapy.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For Further Information
More on the anesthesia, respiratory, and sleep management devices market in the US can be found in a series of reports published by iData Research entitled the US Market Report Suite for Anesthesia, Respiratory, and Sleep Management Devices. The full report suite on the US market for anesthesia, respiratory, and sleep management devices includes segments for anesthesia delivery units (ADU), anesthesia monitors, anesthesia information management systems (AIMS), anesthesia disposables, ventilators, nebulizers, respiratory disposables, oxygen therapy devices, sleep apnea devices and sleep diagnostic devices.
The iData report series on anesthesia, respiratory, and sleep management devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxembourg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about anesthesia, respiratory, and sleep management market data, register online or email us at [email protected] for a US Market Report Suite for Anesthesia, Respiratory, and Sleep Management Devices brochure and synopsis.